SURF, Neurodevelopment, Growth Study in SGA Infants

Infant, Small for Gestational Age Clinical Trial

Official title:

Neurodevelopment, Growth, and Metabolic Syndrome Biomarkers in Term Small-for-gestational-age Infants Fed Standard or Nutrient-enriched Formula

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT04360967
• Other study ID #: 14.11.INF
• Status: Withdrawn
• Phase: N/A
• Start date: March 31, 2017
• Est. completion date: June 2, 2017

Study information

• Verified date: April 2020
• Source: Nestlé
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to determine whether term SGA infants who are fed a nutrient-enriched pre-term formula will have a higher cognitive score, a more appropriate length-for-age Z-score (leading to a lower prevalence of Stunting) but higher blood pressure at 2 years of age compared to term SGA infants who are fed on a regular starter formula.

Description:

This is multi-sites, interventional, double-blinded, randomized, 2-arm parallel-group clinical trial. Two HM fed groups will be included as comparator group.

The primary objectives are:

1. To evaluate neurodevelopment at 2 years of age in term small-for-gestational age (SGA) infants fed standard formula or nutrient-enriched formula from 1 to 6 months of age and compare to each human milk (HM)-fed group.

2. To evaluate length-for-age Z-score at 2 years of age in term SGA infants fed standard formula or nutrient-enriched formula from 1 to 6 months of age and compare to each HM-fed group.

3. To evaluate systolic blood pressure at 2 years of age in term SGA infants fed standard formula or nutrient-enriched formula from 1 to 6 months of age and compare to each HM-fed group.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: June 2, 2017
• Est. primary completion date: June 2, 2017
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: N/A to 44 Days

Eligibility

Inclusion Criteria:

1. Having obtained his/her parents' (or his/her legally accepted representative's LAR's]) written informed consent and having evidence of a personally signed and dated informed consent document indicating that the infant's parents/LAR have been informed of pertinent aspects of the study.

2. For infants in formula fed groups only: infants who require formula feeding due to lactation failure after minimum 2 rounds of breastfeeding counselling.

3. Birth Weight < 10th percentile at term using the 2013 INTERGROWTH-21st Growth Charts for girls and boys.

4. Full term birth (gestational age = 37 weeks and = 41 weeks + 6 days), with gestational age estimated using fetal anthropometry by ultrasonography in early 1st trimester of pregnancy or calculated using the first day of the last menstrual period + 40 weeks if fetal anthropometry data for term calculation is not available or was collected after the 1st trimester.

5. Age <45 days at time of enrollment

6. For infants in the HM-fed AGA comparator group only: born to mothers with pre-pregnancy body mass index (BMI) = 18.5 and <25kg/m2

Exclusion Criteria:

1. mothers with Type-1 Diabetes

2. mothers who smoked >10 cigarettes per day during pregnancy.

3. mothers who used Illicit drugs (e.g. marijuana, cocaine, amphetamines, or heroin) or alcohol (>3 alcoholic beverages per week) during pregnancy

4. Suspected or documented systemic or congenital infections (e.g Human Immunodeficiency virus, cytomegalovirus)

5. Genetic or any other type of congenital malformations, metabolic, cardiovascular, gastrointestinal, pancreatic or hepatic diseases or medical conditions that could compromise growth and/or food intake.

6. Fit to be discharged from neonatal intensive care unit (NICU) in > 5 consecutive days with the exception of infants in the NICU due to jaundice only.

7. Known or suspected intolerance/ allergy to milk protein or any ingredient in the study formulas

8. For infants in the HM-fed groups only: infants who are consuming fortified human milk or formula.

9. Participation in any other interventional clinical trial during the 14 days prior to enrollment.

10. Infants or infant's family who in the investigator's judgement cannot be expected to comply with the protocol or study procedures.

Related Conditions & MeSH terms

• Infant, Small for Gestational Age

Intervention

Other:
• Standard Formula
Standard Formula
• Nutrient-enriched Formula
Nutrient-enriched Formula

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Nestlé

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Evaluation of neurodevelopment	Assessed using Bayley Scales of Infant and Toddler Development® - Third Edition - (To compare with the standard Bayley scores).	at the baseline (2 years of age)
Primary	Evaluation of length-for-age Z-score	Using the WHO growth chart	Evaluated once at 2 years of age
Primary	Systolic Blood pressure	Systolic and diastolic blood pressure measurement from 1 to 6 months of age	at baseline (2 years of age)
Secondary	Evaluation of insulin sensitivity	HOMA-IR (Homeostatic Model Assessment - Insulin Resistance) calculated from Basal (Fasting) plasma glucose and insulin concentrations.	at Baseline ( 2 years of age).
Secondary	Evaluation of insulin sensitivity	HOMA-IR (Homeostatic Model Assessment - Insulin Resistance) calculated from Basal (Fasting) plasma glucose and insulin concentrations.	at last visit ( 5 years of age).
Secondary	Neurodevelopment	Assessed using Wechsler Preschool and Primary Scale of Intelligence™ - Fourth Edition (WPPSI-IV) - (to compare the scores against the standard scores).	At last visit ( 5 years of age)
Secondary	Safety (Adverse Event reporting)	Assessed by Type, incidence, severity, seriousness and relationship to study formulas of AEs (including Infection) among the study subjects.	From 1 to 6 months of age & 6 months to 5 years of age.
Secondary	Growth (Length)	Evaluation of length-for-age in each formula-fed group by Percentages of study population with length-for-age Z-score less than 2.5th, 5th and 10th Percentile on the WHO reference curve(<2.5th percentile indicating prevalence of stunting).	At 2 years of age
Secondary	Growth (Weight)	Evaluation of weight-for-age in each formula-fed group by Percentages of study population with length-for-age Z-score less than 2.5th, 5th and 10th Percentile on the WHO reference curve(<2.5th percentile indicating prevalence of stunting).	At 2 years of age
Secondary	Growth (Head circumference)	Evaluation of head circumference-for-age in each formula-fed group by Percentages of study population with length-for-age Z-score less than 2.5th, 5th and 10th Percentile on the WHO reference curve(<2.5th percentile indicating prevalence of stunting).	At 2 years of age
Secondary	Growth (Z-Scores)	Evaluation of weight-for-length Z-scores in each formula-fed group by Percentages of study population with length-for-age Z-score less than 2.5th, 5th and 10th Percentile on the WHO reference curve(<2.5th percentile indicating prevalence of stunting).	At 2 years of age
Secondary	Evaluation of serum markers of bone metabolism	Assessed by Incidence of abnormal serum (Calcium, phosphorus, Alkaline phosphatase).	At visit 1 (<44 days)
Secondary	Evaluation of serum markers of bone metabolism	Assessed by Incidence of abnormal serum (Calcium, phosphorus, Alkaline phosphatase).	At visit 4 (6 months)
Secondary	Evaluation of urinary markers of bone metabolism	Assessed by Incidence of urine biochemistries (calcium, phosphorous).	At visit 1 (<44 days)
Secondary	Evaluation of urinary markers of bone metabolism	Assessed by Incidence of urine biochemistries (calcium, phosphorous).	At visit 4 (6 months)
Secondary	Body fat mass (%)	Assessed by Deterium dilution	evaluated until 5 years of age.